MAETZOLD DEREK J sold $6K of CSTL (indirect holdings)
MAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 278 indirectly-held shares of CASTLE BIOSCIENCES INC (CSTL) at $20.86 on 2026-06-01 under a Rule 10b5-1 trading plan.
Insider selling under a pre-arranged 10b5-1 plan is typically low-signal, but it can slightly affect near-term sentiment.
Castle Biosciences CEO sold 278 shares in an open-market transaction disclosed via SEC Form 4 on June 1 under a 10b5-1 plan.
Likely limited immediate price impact; any reaction should be small unless accompanied by other catalysts.
Background
SEC Form 4 reports insider transactions; this one is an open-market sale by the CEO under a pre-arranged Rule 10b5-1 plan.
Why it matters
The disclosure updates insider activity records but does not provide new business or clinical information.
Market relevance
Traders may monitor for follow-on insider activity, but this specific transaction is unlikely to be a standalone catalyst.
Market effects
Minimal—this is company-specific insider activity with no stated operational/clinical/regulatory change.
None indicated.
None indicated.
Alternative perspectives
Because it’s a 10b5-1 sale, the market may overreact; the action may reflect routine liquidity rather than negative fundamentals.
The filing does not indicate why shares were sold; traders should check for any concurrent buys/sales by other insiders or larger transactions in nearby filings.
Key entities
- issuerCASTLE BIOSCIENCES INC
Subject of the SEC Form 4 insider sale by CEO Derek J. Maetzold.
- insiderMAETZOLD DEREK J
Pres. & Chief Exec. Officer who sold 278 shares on June 1 under a 10b5-1 plan.